Phase 2 Randomized, Non-Comparative Study of Ticilimumab or Best Supportive Care Immediately Following First-Line, Platinum-Based Therapy in Patients with STage IIIB (with effusion) IV Non-Small Cell Lung Cancer that has Responded or Remained Stable

Grants and Contracts Details

StatusFinished
Effective start/end date6/1/065/31/10

Funding

  • Pfizer Inc.: $26,801.00